Modulación de la vía JAK/STAT/SOCS y sus implicaciones terapéuticas en cáncer y enfermedades inflamatorias

This article critically reviews the literature on JAK/STAT pathway biology, its roles in myeloproliferative, inflammatory, and neoplastic diseases, and advances in targeted pharmacological inhibition. The evidence reviewed indicates that cytokine-mediated JAK/STAT activation regulates essential cellular functions. Several inhibitors, including ruxolitinib, tofacitinib, and baricitinib, have demonstrated clinical efficacy in specific approved indications, such as myelofibrosis and rheumatoid arthritis. However, approved uses vary by drug and jurisdiction, while experimental compounds require further clinical validation. These findings underscore the pathway’s therapeutic relevance and the importance of distinguishing established clinical uses from preclinical evidence.

Authors

Institutions

Publication Details

Journal
Ibero Ciencias - Revista Científica y Académica
Published
2026-11-13
DOI
https://doi.org/10.63371/ic.v5.n4.a1878
Primary Topic
Cytokine Signaling Pathways and Interactions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Modulación de la vía JAK/STAT/SOCS y sus implicaciones terapéuticas en cáncer y enfermedades inflamatorias

Jonnathan Guadalupe Santillán Benítez, Erasto Desales Salazar, Mariam Jazive García López
Ibero Ciencias - Revista Científica y Académica
Cytokine Signaling Pathways and Interactions
article

Modulación de la vía JAK/STAT/SOCS y sus implicaciones terapéuticas en cáncer y enfermedades inflamatorias

Jonnathan Guadalupe Santillán Benítez, Erasto Desales Salazar, Mariam Jazive García López
article en

Abstract

This article critically reviews the literature on JAK/STAT pathway biology, its roles in myeloproliferative, inflammatory, and neoplastic diseases, and advances in targeted pharmacological inhibition. The evidence reviewed indicates that cytokine-mediated JAK/STAT activation regulates essential cellular functions. Several inhibitors, including ruxolitinib, tofacitinib, and baricitinib, have demonstrated clinical efficacy in specific approved indications, such as myelofibrosis and rheumatoid arthritis. However, approved uses vary by drug and jurisdiction, while experimental compounds require further clinical validation. These findings underscore the pathway’s therapeutic relevance and the importance of distinguishing established clinical uses from preclinical evidence.

Ibero Ciencias - Revista Científica y AcadémicaVol. 5(4)
Universidad Autónoma del Estado de México (MX)
Cytokine Signaling Pathways and Interactions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon